ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

17-Jul-2013 - ADC Therapeutics Sarl and BZL Biologics LLC announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers. PSMA is a cell-surface antigen on prostate cancer cells, and PSMA levels correlate directly with an aggressive, metastasizing ...

Prosensa receives rare disease 'Company Award' from EURORDIS

12-Mar-2013 - Prosensa received the ‘Company Award’ at the EURORDIS Black Pearl Gala Dinner in Brussels. The Black Pearl Gala Dinner is hosted annually by EURORDIS, a non-governmental alliance of patients and patient organizations active in the field of rare diseases, to celebrate Rare Disease Day. Awards ...

Molecular Partners: Results from Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema

23-Jan-2013 - Molecular Partners announced that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published in The American Journal of Ophthalmology (AJO). MP0112 was shown to be ...

Hookipa announces formation of Scientific Advisory Board

14-Jan-2013 - Hookipa Biotech AG announced the formation of its Scientific Advisory Board (SAB). The SAB is chaired by Emeritus Prof. Dr. Paul-Henri Lambert (PhD), former Chief of Vaccine Research and Development for the WHO Global Program for Vaccines and Immunizations. The members include scientists and ...

FuturaGene and EMBRAPA sign an umbrella Cooperation Framework Agreement

03-Dec-2012 - FuturaGene announced the signing of a Cooperation Framework Agreement with EMBRAPA, (Empresa Brasileira de Pesquisa Agropecuária) the Brazilian Ministry of Agriculture research organisation. Under the agreement, FuturaGene and EMBRAPA will establish collaborative research programs in eucalyptus ...

OGT opens New York office and appoints US sales team

22-Nov-2012 - Oxford Gene Technology (OGT) announced that it has opened a new office in Tarrytown, New York to support and grow its cytogenetics arrays and next generation sequencing business in the US.The new office will enable OGT to provide hands-on technical support and training to its existing US ...

Marinomed Granted Chinese Patent for Antiviral Polymer

21-Nov-2012 - Marinomed Biotechnologie GmbH announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.Dr. Andreas Grassauer, CEO and ...

AmpliPhi and Special Phage Services complete merger

20-Nov-2012 - AmpliPhi Biosciences Corporation and Special Phage Services (SPS) are formally combined following the completion of the share exchange transaction. Now trading as Ampliphi, the enlarged company combines complementary technologies and expertise in bacteriophage-based therapies to create an ...

MiReven announces positive preclinical results for miR-7 in head and neck cancer

26-Oct-2012 - MiReven announced the publication in the journal PLOS One of a study in which miR-7 was examined in combination with the head and neck cancer (HNC) treatment erlotinib hydrochloride (Tarceva, Genentech/OSIP).Epidermal growth factor (EGFR) inhibitors are effective in only 20-30% of patients with ...

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy

£10m in milestone payments received from GlaxoSmithKline

24-Oct-2012 - Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055, ...